Editas Medicine Inc stock is traded at $1.72, with a volume of 1,786,582. It is down -2.82% in the last 24 hours and down -28.93% over the past month. Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Previous Close:
$1.77
Open:
$1.80
24h Volume:
1,786,582
Relative Volume:
0.74
Market Cap:
$265.46M
Revenue:
$38.69M
Net Income/Loss:
-$108.95M
P/E Ratio:
-
EPS:
-$1.22
Net Cash Flow:
-$141.09M
1W Performance:
-19.63%
1M Performance:
-28.93%
6M Performance:
-30.08%
1Y Performance:
-31.75%
1-Day Range:
$1.70$1.83
1-Week Range:
$1.70$2.21
52-Week Range:
$1.66$3.94
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine IncSector
HealthcareIndustry
BiotechnologyPhone
617-401-9000Address
11 HURLEY ST., CAMBRIDGE, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS